Trial · NCT07913958

The Effect of Aerobic and Resistance Training With and Without Neurodynamic Exercises on Chemotherapy-induced Peripheral Neuropathy Symptoms and Associated Neuro-immune Mechanisms

NCT07913958, Not applicable, Not yet recruiting, Universiteit Antwerpen

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Effect of Aerobic and Resistance Training With and Without Neurodynamic Exercises on Chemotherapy-induced Peripheral Neuropathy Symptoms and Associated Neuro-immune Mechanisms. Trials, record NCT07913958. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913958

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Effect of Aerobic and Resistance Training With and Without Neurodynamic Exercises on Chemotherapy-induced Peripheral Neuropathy Symptoms and Associated Neuro-immune Mechanisms
NCT number: NCT07913958
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 87 participants, estimated
Lead sponsor: Universiteit Antwerpen
Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Aerobic + resistance training, Neurodynamic exercises, Physical activity advice, Activity tracker
First posted: 2026-11-03
Last updated: 2026-11-09

Source ClinicalTrials.gov

Registered outcomes24

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Chemotherapy-induced peripheral neuropathy (CIPN) sensory symptom severity	at baseline and 12 weeks follow-up	Sensory symptom severity assessed using the sensory subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-item scale (EORTC QLQ-CIPN20). Scores range from 9 to 36, with higher scores indicating greater sensory symptom severity.
Secondary	Chemotherapy-induced peripheral neuropathy (CIPN) sensory, motor and autonomic symptom severity	at baseline, 4, 8, 12 and 24 weeks follow-up	Sensory, motor and autonomic symptoms of CIPN measured using the sensory, motor and autonomic subscale of the Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20). Each subscale score will be linearly transformed to a 0-100 scale with higher scores indicating greater symptom burden.
Secondary	Chemotherapy-induced peripheral neuropathy (CIPN) signs	at baseline, 12 and 24 weeks follow-up	The Total Neuropathy Score clinical version (TNSc) is used to evaluate motor symptoms, pin sensation, vibration sensibility, tendon reflexes and strength in the hands and feet (score range 0-20, higher scores indicating greater severity of neuropathy).In addition, quantitative sensory testing (QST) is performed to assess sensory nerve function, including vibration, thermal and mechanical detection and pain thresholds. Together, these measures provide a comprehensive assessment of clinical signs and sensory dysfunction associated with CIPN.
Secondary	Pain severity hands and feet	at baseline, 4, 8, 12 and 24 weeks follow-up	Pain severity in the hands and feet will be evaluated with a Visual Analogue Scale (VAS). Four VAS scales will be completed: pain intensity at the present moment, mean pain intensity (global average pain intensity over the past week), maximum pain intensity (pain intensity at its maximum over the past week) and minimum pain intensity (pain intensity at its minimum over the past week).
Secondary	General pain location and interference	at baseline, 12 and 24 weeks follow-up	Pain location and pain interference will be evaluated with the Brief Pain Inventory (BPI), including a body diagram to identify painful body areas and a pain interference section measuring how pain impacts various aspects of daily life, including mood, sleep, work and social activities (score range 0-70, higher scores mean a worse outcome).
Secondary	Physical functioning	at baseline, 12 and 24 weeks follow-up	Evaluated with the PROMIS Short Form v2.0 Physical Function 8a questionnaire (scores expressed as T-scores with a mean of 50 (SD = 10) in the general population, higher scores mean a better outcome).
Secondary	Self-reported physical activity	at baseline, 12 and 24 weeks follow-up	Self-reported levels of physical activity are measured using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GLTPAQ/GLTEQ). The score is calculated based on the weekly frequency of strenuous, moderate, and mild leisure-time physical activity sessions lasting more than 15 minutes. Higher scores indicate higher levels of self-reported physical activity.
Secondary	Objective physical activity	at baseline, 12 and 24 weeks follow-up	Minutes spent in different intensity zones (sedentary, light, moderate, vigorous) will be collected using a Fitbit device.
Secondary	Fatigue	at baseline, 12 and 24 weeks follow-up	Evaluated with the Multidimensional Fatigue Inventory (score range 20-100, higher scores mean a worse outcome).
Secondary	Sleep disturbance	at baseline, 12 and 24 weeks follow-up	Evaluated with the PROMIS Short Form v1.0 Sleep Disturbance 8a questionnaire (scores expressed as T-scores with a mean of 50 (SD = 10) in the general population, higher scores mean a worse outcome).

1 to 10 of 24Source ClinicalTrials.gov

See all 24 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07913958

GET https://conductscience.org/api/trials/v1/NCT07913958/registered?page=2

API reference For AI assistants